Health Canada approves Kane Biotech’s KBI disinfectant

Use has been broadened to include hospitals and food processing facilities

Health Canada has approved the use of Kane Biotech’s KBI antibacterial hard surface disinfectant in hospitals and the food processing industry.

A supplemental DIN application was submitted to Health Canada for the widening of the disinfectant’s use. The KBI disinfectant has already received a Drug Identification Number or DIN (02374463) for the Canadian household domestic use market. The new application included supporting data on the broad-spectrum antimicrobial efficacy of KBI against bacteria associated with hospital-acquired infections and food-borne diseases.

Our broad-spectrum disinfectant could be very useful in containing bacterial contamination in food manufacturing facilities

“The Health Canada approval for the additional sites of use opens the doors for KBI applications in hospitals, hotels, restaurants, and food manufacturing industries,” said Gord Froehlich, president and CEO of Kane Biotech.

“Our broad-spectrum disinfectant could be very useful in containing the bacterial contaminations in food manufacturing facilities resulting in food-borne disease outbreaks.”

Kane Biotech says the KBI disinfectant is effective against Methicillin-resistant S. aureus (MRSA), Pseudomonas aeruginosa, Vancomycin-Resistant Enterococci (VRE), Klebsiella pneumoniae and Acinetobacter baumannii.

It is also effective against E. coli O157, Listeria and Salmonella that caused recent outbreaks of food-borne diseases due to contamination in food processing facilities.

The Kane Biotech is a developer of products that prevent and remove microbial biofilms. Biofilms are a major cause of a number of serious medical problems including chronic infections and medical device related infections. They develop on surfaces such as catheters, prosthetic implants, teeth, lungs and the urogenital tract.

Companies